IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

Not Recruiting

Trial ID: NCT06087029


The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

Official Title

IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

Stanford Investigator(s)

Dominik Fleischmann
Dominik Fleischmann

Professor of Radiology (Cardiovascular Imaging)


Inclusion Criteria:

   1. Age > 21 years

   2. Stanford type B aortic dissection not involving the aorta at or proximal to the
   innominate artery, without rupture and/or malperfusion (renal, mesenteric, or

   3. Acuity: within 48 hours - 6 weeks of index admission

   4. Ability to provide written informed consent and comply with the protocol

Exclusion Criteria:

   1. Ongoing systemic infection

   2. Pregnant or planning to become pregnant in the next 3 months

   3. Life expectancy related to non-aortic conditions < 2 years

   4. Unwilling or unable to comply with all study procedures including serial imaging

   5. Known patient history of genetic aortopathy

   6. Penetrating Aortic Ulcer and Intramural hematoma

   7. Iatrogenic (traumatic) aortic dissection

   8. Previous aortic dissection or aortic surgery

   9. Prior aortic aneurysmal disease


procedure: TEVAR

other: Guideline directed medical therapy and surveillance of dissection

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305